Axonics Names Kari Keese as Finance Chief

Axonics announced that president and chief financial officer (CFO) Dan L. Dearen is retiring from the company. VP of finance and accounting Kari Keese will succeed him on October 2.
 
“On behalf of the Axonics team and the board of directors, I want to thank Dan, my co-founder and longtime colleague, for his many contributions to the company over the last 10 years,” Raymond W. Cohen, CEO of Axonics told the press. “Dan has played an instrumental role in Axonics’ success and the significant value that has been created for the company’s shareholders. We wish Dan all the best on his retirement.”
 
Dearen added, “It has been a privilege working alongside the talented, mission-driven team at Axonics. I am incredibly proud of the impact the company’s therapies have had on improving the quality of life for tens of thousands of incontinence patients. I will follow Axonics with pride as it continues on its path to market leadership.”
 
Keese leads Axonic’s finance and accounting functions. She joined the company in 2014 as was previously director of finance and controller. Before Axonics, she was controlled at Vessix Vascular, a company headed by Cohen and Dearen that was acquired by Boston Scientific in late 2012. She began her career in public accounting.
 
Cohen added, “Kari has been with Axonics for over nine years and has served as a valuable member of our senior management team. She is a seasoned executive and we are confident that she will excel as our next chief financial officer. Kari’s deep knowledge of the company and track record of financial leadership make her an ideal successor to Dan.”
 
Axonics also reaffirmed fiscal year 2023 revenue guidance of $358 million, previously provided on July 27. The company acquired lead placement technology for its sacral neuromodulation device from Radian LLC in April.